SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa ¢ » ¢ Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling progression to highest dose of Part 1 of the PRODYGY trial Favorable safety and tolerability profiles observed with first two SPVN06 doses across six patients (three patients per cohort) Exploration of SPVN06 in geographic atrophy to begin in 2024 Paris, 24 January 2024 – SparingVision ("the Company"), a clinical-s ...